FI95259B - Förfarande för framställning av farmaceutiskt aktiva 7-substituerade-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-oner - Google Patents
Förfarande för framställning av farmaceutiskt aktiva 7-substituerade-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-oner Download PDFInfo
- Publication number
- FI95259B FI95259B FI914015A FI914015A FI95259B FI 95259 B FI95259 B FI 95259B FI 914015 A FI914015 A FI 914015A FI 914015 A FI914015 A FI 914015A FI 95259 B FI95259 B FI 95259B
- Authority
- FI
- Finland
- Prior art keywords
- formula
- amino
- pyrimidin
- dihydro
- pyrrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1 H /A. N HN Y--\ (I) 10 \ AAV h2n n CHjAr 15 vari (a) -CHjAr är R R 1 2 väri (i) R, är väte, halogen, C,-C3-alkyl, C,-C3-alkoxi, bensyloxi eller hydroxi och R2 är väte, halogen, C,-C3-alkyl,
20 C,-C3-alkoxi, bensyloxi eller hydroxi, (ii) R, är väte eller C,-C3-alkyl och R2 är trifluormetyl eller (iii) R, är tri-fluormetyl och R2 är väte eller C,-C3-alkyl; eller (b) -CH2Ar är f^CH~ \ / x 25 väri X är svavel eller syre och vari anslutningen till tio-fen- eller furanringen är i 2- eller 3-positionen; eller en tautomer därav, kannetecknat av att en forening med formeln li 27 95259 H r3o2c. .n. (V) R4CNH-C=N CHjAr Il I 10. sr5 väri Ar har ovan angiven betydelse, R3 är lägre alkyl, R4 är karbocyklisk aryl, säsom fenyl, och Rs är lägre alkyl, kon-denseras genom att omsätta denna förening med vattenfri am-15 moniak och cykliseras vid förhöjd temperatur, varvid man erhäller en förening med formeln I, och om sä önskas, i) debensyleras en förening med formeln I, väri R] och/el-ler R2 är bensyloxi, varvid man erhäller motsvarande förening med formeln I, väri Rj och/eller R2 är hydroxi, eller 2 0 ii) dehalogeneras en förening med formeln I, väri R, och/el ler R2 är halogen, varvid man erhäller motsvarande förening med formeln I, väri R, och/eller R2 är väte.
1. Förfarande för framställning av en farmaceutiskt aktiv 7-substituerad-2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimi-din-4-on med formeln 5 0
2. Förfarande enligt patentkrav 1, kannetecknat av att man 25 framställer 2-amino-3,5-dihydro-7-(3-klorfenylmetyl)-4H-pyr- rolo[3,2-d]pyrimidin-4-on.
3. Förfarande enligt patentkrav 1, kannetecknat av att man framställer 2-amino-3,5-dihydro-7 -(fenylmetyl)-4H-pyrrolo- 30 [3,2-d]pyrimidin-4-on.
4. Förfarande enligt patentkrav 1, kannetecknat av att man framställer 2-amino-3,5-dihydro-7-(3-tienylmetyl)-4H-pyrro- 1o[3,2 -d]pyrimidin-4 -on. 35
5. Förfarande enligt patentkrav 1, kännetecknat av att man framställer 2-amino-3,5-dihydro-7-(2-furanylmetyl)-4H-pyrro-lo[3,2-d]pyrimidin-4-on.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31606389A | 1989-02-27 | 1989-02-27 | |
| US31606389 | 1989-02-27 | ||
| US9001021 | 1990-02-27 | ||
| PCT/US1990/001021 WO1990010631A1 (en) | 1989-02-27 | 1990-02-27 | 9-substituted-8-unsubstituted-9-deazaguanines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI914015A0 FI914015A0 (sv) | 1991-08-26 |
| FI95259B true FI95259B (sv) | 1995-09-29 |
| FI95259C FI95259C (sv) | 1996-01-10 |
Family
ID=23227309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI914015A FI95259C (sv) | 1989-02-27 | 1991-08-26 | Förfarande för framställning av farmaceutiskt aktiva 7-substituerade-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-oner |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5565463A (sv) |
| EP (1) | EP0460116B1 (sv) |
| JP (1) | JP2760364B2 (sv) |
| KR (1) | KR100208315B1 (sv) |
| AT (1) | ATE157363T1 (sv) |
| AU (1) | AU640649B2 (sv) |
| CA (1) | CA2047216C (sv) |
| DE (1) | DE69031337T2 (sv) |
| DK (1) | DK0460116T3 (sv) |
| ES (1) | ES2106732T3 (sv) |
| FI (1) | FI95259C (sv) |
| HU (1) | HU217870B (sv) |
| NO (1) | NO180049C (sv) |
| RU (1) | RU2093513C1 (sv) |
| WO (1) | WO1990010631A1 (sv) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0500653A4 (en) * | 1989-10-31 | 1995-08-23 | Biocryst Inc | Inhibitors of purine nucleoside phosphorylase |
| US5726311A (en) * | 1989-11-29 | 1998-03-10 | Biocryst Pharmaceuticals, Inc. | 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same |
| US5236926A (en) * | 1992-02-03 | 1993-08-17 | Warner-Lambert Company | 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions |
| AU6855594A (en) | 1993-06-30 | 1995-01-24 | Biocryst Pharmaceuticals, Inc. | 9-deazahypoxanthines as pnp inhibitors |
| US5650511A (en) * | 1995-12-12 | 1997-07-22 | Biocryst Pharmaceuticals, Inc. | Process for the preparation of 9-deazaguanine derivatives |
| AR012871A1 (es) * | 1997-05-29 | 2000-11-22 | Novartis Ag | 2-amino-7-(2-hidroxietilo-1-sustituido)-3,5-dihidropirrolo (3,2-d)pirimidin -4-onas, composiones farmaceuticas y el uso de las mismas para la manufacturade un medicamento. |
| US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
| US6174888B1 (en) | 1998-05-28 | 2001-01-16 | Novartis Ag | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| US7763257B2 (en) | 2004-12-09 | 2010-07-27 | Christina Juneau | Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products |
| UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
| WO2014205194A1 (en) | 2013-06-22 | 2014-12-24 | Nitor Therapeutics | Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer |
| WO2020186187A1 (en) | 2019-03-13 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
| GB202218782D0 (en) | 2022-12-13 | 2023-01-25 | Mehrling Thomas | Purine nucleoside phosphorylase inhibitor for metabolic syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL76546A (en) * | 1984-10-12 | 1988-12-30 | Warner Lambert Co | 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them |
| US4772606A (en) * | 1985-08-22 | 1988-09-20 | Warner-Lambert Company | Purine derivatives |
| IE60433B1 (en) * | 1986-08-26 | 1994-07-13 | Warner Lambert Co | Novel 9-deazaguanines |
| US4923872A (en) * | 1986-08-26 | 1990-05-08 | Warner-Lambert Co. | Analogues of pyrrolo[3,2d]pyrimidin-4-ones |
| CA1294960C (en) * | 1986-10-24 | 1992-01-28 | Thomas C. Malone | 7-deazaguanines as immunomodulators |
| NO169490C (no) * | 1988-03-24 | 1992-07-01 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater |
| DE58902899D1 (de) * | 1988-12-14 | 1993-01-14 | Ciba Geigy Ag | 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer. |
-
1990
- 1990-02-27 AU AU55248/90A patent/AU640649B2/en not_active Ceased
- 1990-02-27 ES ES90906624T patent/ES2106732T3/es not_active Expired - Lifetime
- 1990-02-27 DE DE69031337T patent/DE69031337T2/de not_active Expired - Fee Related
- 1990-02-27 HU HU463/90A patent/HU217870B/hu not_active IP Right Cessation
- 1990-02-27 JP JP2506410A patent/JP2760364B2/ja not_active Expired - Lifetime
- 1990-02-27 AT AT90906624T patent/ATE157363T1/de not_active IP Right Cessation
- 1990-02-27 CA CA002047216A patent/CA2047216C/en not_active Expired - Fee Related
- 1990-02-27 EP EP90906624A patent/EP0460116B1/en not_active Expired - Lifetime
- 1990-02-27 WO PCT/US1990/001021 patent/WO1990010631A1/en active IP Right Grant
- 1990-02-27 DK DK90906624.3T patent/DK0460116T3/da active
- 1990-02-27 RU SU915001541A patent/RU2093513C1/ru active
- 1990-02-27 KR KR1019910701003A patent/KR100208315B1/ko not_active IP Right Cessation
-
1991
- 1991-08-26 FI FI914015A patent/FI95259C/sv active
- 1991-08-26 NO NO913332A patent/NO180049C/no unknown
-
1994
- 1994-01-18 US US08/181,979 patent/US5565463A/en not_active Expired - Fee Related
-
1996
- 1996-08-02 US US08/691,230 patent/US5721240A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK0460116T3 (da) | 1998-03-30 |
| DE69031337T2 (de) | 1998-03-05 |
| HUT58737A (en) | 1992-03-30 |
| CA2047216A1 (en) | 1990-08-28 |
| AU5524890A (en) | 1990-10-09 |
| JPH04503675A (ja) | 1992-07-02 |
| JP2760364B2 (ja) | 1998-05-28 |
| NO180049B (no) | 1996-10-28 |
| WO1990010631A1 (en) | 1990-09-20 |
| EP0460116A4 (en) | 1992-05-13 |
| DE69031337D1 (de) | 1997-10-02 |
| ES2106732T3 (es) | 1997-11-16 |
| EP0460116B1 (en) | 1997-08-27 |
| FI95259C (sv) | 1996-01-10 |
| NO913332L (no) | 1991-08-26 |
| EP0460116A1 (en) | 1991-12-11 |
| US5565463A (en) | 1996-10-15 |
| FI914015A0 (sv) | 1991-08-26 |
| HU217870B (hu) | 2000-04-28 |
| KR920701209A (ko) | 1992-08-11 |
| NO913332D0 (no) | 1991-08-26 |
| CA2047216C (en) | 1999-03-30 |
| US5721240A (en) | 1998-02-24 |
| AU640649B2 (en) | 1993-09-02 |
| ATE157363T1 (de) | 1997-09-15 |
| RU2093513C1 (ru) | 1997-10-20 |
| KR100208315B1 (ko) | 1999-07-15 |
| NO180049C (no) | 1997-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016282828B2 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| US5935964A (en) | 1,2,4-triazolo 1,5-c! pyrimidine heterocyclic analogues having antagonistic activity on adenosine A2a receptor | |
| US5736549A (en) | Hypoxanthine and guanine compounds | |
| FI95259B (sv) | Förfarande för framställning av farmaceutiskt aktiva 7-substituerade-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-oner | |
| US6545000B1 (en) | [1,2,4]triazolo[1,5-c]pyrimidine derivatives | |
| DE60219672T2 (de) | Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften | |
| US5840895A (en) | Triazole intermediates for tricyclic benzazepine and benzothiazepine derivatives | |
| WO1999043678A1 (fr) | Medicaments et prophylaxie contre la maladie de parkinson | |
| US5663339A (en) | Process for preparing 5-substituted pyrrolo-[2,3-D] pyrimidines | |
| US5968946A (en) | Heterocyclic derivatives useful in treating central nervous system disorders | |
| Sztanke et al. | Synthesis, structure elucidation and in vitro anticancer activities of novel derivatives of diethyl (2E)-2-[(2E)-(1-arylimidazolidin-2-ylidene) hydrazono] succinate and ethyl (4-oxo-8-aryl-4, 6, 7, 8-tetrahydroimidazo [2, 1-c][1, 2, 4] triazin-3-yl) acetate | |
| EP0880524A1 (de) | Neue triazolopurine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| EP1590355A1 (fr) | Derives d azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| JP2004535405A (ja) | 新しい三環式ジヒドロキノリン化合物、これらの製造方法及びこれらを含む医薬組成物 | |
| US3595874A (en) | 3,4,5,10-tetrahydroazepino(2,3-b)indol-5a (2h)-ols | |
| WO2014115171A1 (en) | Triazine compounds and a process for preparation thereof | |
| SK279997B6 (sk) | 2,4,8-trisubstituované-4,5-dihydro-5-oxo-3h,6h-1,4 | |
| FI88036B (fi) | Foerfarande foer framstaellning av saosom bensodiazepinreceptoragonister/antagonister anvaendbara 2-aryl-tetrahydro(pyrido- och pyrrolo)/e//1,2,4/triazolo/1,5-c/pyrimidoner | |
| JP2000044572A (ja) | 新規８Ｈ―チエノ―〔２，３―ｂ〕ピロリジン―８―オン化合物、その製造の方法及びそれらを含む医薬組成物 | |
| JPS61233688A (ja) | ベンゼン縮合複素環化合物 | |
| JPH09504789A (ja) | ５−ｈｔ１ａレセプターに対して親和性をもつ三環式化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: BIOCRYST PHARMACEUTICALS, INC. |
|
| BB | Publication of examined application |